#1 Clinical Trials Search in Europe

Ertapenem Sodium

Ertapenem Sodium, also known by its brand name Invanz, is an antibiotic used in various clinical trials to treat different types of infections. These trials aim to evaluate its effectiveness, safety, and pharmacokinetics in different patient populations and conditions, including urinary tract infections, diabetic foot infections, and surgical site infections. The studies also compare Ertapenem Sodium to other antibiotics and explore different administration methods.

Table of Contents

What is Ertapenem?

Ertapenem sodium, also known by its brand name Invanz™ or MK-0826, is a powerful antibiotic medication belonging to the carbapenem class[1]. Carbapenems are a type of antibiotic that are effective against a wide range of bacteria, including some that are resistant to other antibiotics. Ertapenem is particularly useful for treating infections caused by bacteria that produce extended-spectrum beta-lactamases (ESBLs), which are enzymes that can make some bacteria resistant to certain antibiotics[9].

Uses of Ertapenem

Ertapenem is used to treat various types of infections, including:

  • Complicated urinary tract infections (UTIs): These are UTIs that are more severe or difficult to treat than typical UTIs, often involving the kidneys (a condition called pyelonephritis)[1][2].
  • Complicated intra-abdominal infections: These are infections that occur within the abdomen and are typically more serious than simple infections[1].
  • Diabetic foot infections: These are infections that occur in the feet of people with diabetes, which can be particularly serious and difficult to treat[4].
  • Surgical site infections: Ertapenem can be used to prevent infections that might occur after certain types of surgery, such as colorectal surgery[3].

How is Ertapenem Administered?

Ertapenem is typically given as an intravenous (IV) infusion, which means it’s delivered directly into a vein. The standard dose is usually 1 gram given once daily[1][2]. However, the exact dosage and duration of treatment can vary depending on the type and severity of the infection being treated.

In some cases, especially for elderly patients or those with difficult vein access, ertapenem may be given subcutaneously (under the skin). This method is being studied to ensure it’s as effective as IV administration[9].

Some studies have also looked at giving ertapenem as a quick IV injection (called an IV bolus) instead of the standard 30-minute infusion. This could potentially make the administration process quicker and more convenient[5].

Effectiveness of Ertapenem

Ertapenem has been shown to be effective in treating various types of infections. In studies comparing ertapenem to other antibiotics:

  • For complicated UTIs, ertapenem was found to be as effective as ceftriaxone, another commonly used antibiotic[2].
  • In the treatment of diabetic foot infections, ertapenem was shown to be as effective as piperacillin/tazobactam, another powerful antibiotic combination[4].
  • For preventing surgical site infections after colorectal surgery, ertapenem was found to be as effective as the combination of ceftriaxone and metronidazole[3].

Safety and Side Effects

Like all medications, ertapenem can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea
  • Headache
  • Injection site reactions (such as pain or swelling where the medication is given)

More serious side effects are rare but can occur. These may include allergic reactions, liver problems, or changes in blood cell counts. It’s important to report any unusual symptoms to your healthcare provider[4].

Ertapenem in Special Populations

Ertapenem may need to be used differently in certain groups of people:

  • Elderly patients: Studies are being conducted to determine the best way to administer ertapenem in patients over 75 years old, including the possibility of subcutaneous administration[9].
  • Patients with kidney problems: The dosage of ertapenem may need to be adjusted in patients with kidney disease or those undergoing dialysis[8].
  • Burn patients: Research is being done to understand how ertapenem works in patients with severe burns, as their bodies may process medications differently[7].

Ongoing Research

Researchers continue to study ertapenem to better understand how it works in different situations. Some areas of ongoing research include:

  • Using ertapenem to treat tuberculosis, especially in cases where the bacteria are resistant to other antibiotics[6].
  • Understanding how ertapenem works in patients with severe burns[7].
  • Studying the best way to use ertapenem in patients undergoing continuous dialysis[8].
  • Investigating the effectiveness of subcutaneous administration of ertapenem, especially in elderly patients[9].
Aspect Details
Main Indications Complicated urinary tract infections, diabetic foot infections, surgical site infection prevention
Dosage Typically 1 gram daily, administered intravenously
Administration Method 30-minute infusion (standard), 5-minute IV bolus (under study)
Primary Outcomes Clinical response, microbiological response, safety profile
Comparator Drugs Ceftriaxone, Piperacillin/Tazobactam
Special Populations Patients on hemodialysis, burn patients, tuberculosis patients
Pharmacokinetic Measures Maximum plasma concentration (Cmax), Area Under the Curve (AUC)
Safety Monitoring Adverse events, vital signs, blood tests, organ function

FAQ

  • What is Ertapenem Sodium used for in clinical trials? Ertapenem Sodium is being studied for treating various infections, including complicated urinary tract infections, diabetic foot infections, and preventing surgical site infections after colorectal surgery.
  • How is Ertapenem Sodium typically administered in these trials? In most trials, Ertapenem Sodium is administered intravenously (IV) as a single daily dose of 1 gram, usually infused over 30 minutes. Some studies are exploring different administration methods, such as a 5-minute IV bolus.
  • What are the main outcomes measured in Ertapenem Sodium clinical trials? The trials primarily measure the drug's efficacy in treating infections, its safety profile, and pharmacokinetic parameters such as maximum plasma concentration and area under the curve. Some studies also compare Ertapenem Sodium to other antibiotics.
  • Are there any special populations being studied with Ertapenem Sodium? Yes, some trials focus on specific populations such as patients with kidney failure receiving continuous hemodialysis, burn patients, and patients with tuberculosis. These studies help determine appropriate dosing and efficacy in these special populations.
  • What are some of the potential side effects of Ertapenem Sodium observed in clinical trials? While specific side effects aren't detailed in the provided information, the trials monitor for adverse events, including changes in vital signs, blood tests, and any unexpected symptoms. Safety and tolerability are important aspects of these studies.

Ongoing Clinical Trials on Ertapenem Sodium

  • Study of pivmecillinam compared to standard antibiotics for treating Escherichia coli urinary tract infection with fever

    Recruiting

    1 1 1
    Investigated drugs:
    Norway Sweden

  • Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study on Shortened Antibiotic Treatment for Gram-negative Bacteremia in Hospitalized Adults Using Pivmecillinam Hydrochloride and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study of Intravenous Fosfomycin, Tazobactam Sodium, and Ertapenem Sodium for Hospitalized Patients with Complicated Urinary Tract Infections

    Recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study of Temocillin and Meropenem for Patients with Infections Caused by Resistant Enterobacteriaceae

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Efficacy: The ability of a drug to produce the desired therapeutic effect.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Microbiological Response: The effect of an antibiotic on the bacteria causing an infection, often measured by the absence of the original pathogen in follow-up cultures.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, used in pharmacokinetic studies.
  • Minimal Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • Continuous Venovenous Hemodialysis (CVVHD): A type of dialysis used in critically ill patients with kidney failure that provides continuous blood filtration and dialysis.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys.

References

  1. https://clinicaltrials.gov/study/NCT00379951
  2. https://clinicaltrials.gov/study/NCT01014013
  3. https://clinicaltrials.gov/study/NCT01254344
  4. https://clinicaltrials.gov/study/NCT01370616
  5. https://clinicaltrials.gov/study/NCT01148771
  6. https://clinicaltrials.gov/study/NCT01730664
  7. https://clinicaltrials.gov/study/NCT01497990
  8. https://clinicaltrials.gov/study/NCT00877370
  9. https://clinicaltrials.gov/study/NCT02505386